Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab

Immune checkpoint inhibitors are monoclonal antibodies (mAb) belonging to different categories, namely those that block cytotoxic T-lymphocyte-associated protein (CTLA-4) and programmed death 1 (PD1) expressed on T-cells, or programmed-death ligand 1 (PD-L1) expressed on tumour and antigen-presenting cells [1]. Although they have different functions, the common final effect of this class of drugs is the enhancement of the immune response against cancer cells [1]. One of the major PD-L1 inhibitors [...]